Company profile for Neurelis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neurelis was founded to license, develop, and commercialize product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry. Our emphasis is on highly differentiated therapies that empower patients, care partners, and healthcare providers. The benefits of our unique platform technology allow us to form strategic partnerships to address significant unmet needs in other therapeutic areas as wel...
Neurelis was founded to license, develop, and commercialize product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry. Our emphasis is on highly differentiated therapies that empower patients, care partners, and healthcare providers. The benefits of our unique platform technology allow us to form strategic partnerships to address significant unmet needs in other therapeutic areas as well.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3430 Carmel Mountain Road, Suite 300 San Diego, CA 92121
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/neurelis-to-present-clinical-data-at-american-epilepsy-society-annual-meeting-302633639.html

PR NEWSWIRE
05 Dec 2025

https://www.prnewswire.com/news-releases/neurelis-to-participate-in-sofies-journey-epilepsy-awareness-day-and-education-expo-at-disneyland-resort-302608961.html

PR NEWSWIRE
10 Nov 2025

https://www.prnewswire.com/news-releases/neurelis-to-present-study-of-nrl-1049-a-rho-kinase-rock-inhibitor-with-potential-to-treat-symptomatic-cerebral-cavernous-malformations-ccm-at-annual-ccm-meeting-302605912.html

PR NEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/neurelis-to-highlight-data-from-a-study-of-diazepam-nasal-spray-in-pediatric-patients-at-the-child-neurology-society-annual-meeting-302577755.html

PR NEWSWIRE
08 Oct 2025

https://www.prnewswire.com/news-releases/neurelis-will-highlight-analyses-of-seizure-treatment-with-diazepam-nasal-spray-at-the-american-academy-of-neurology-annual-meeting-302421290.html

PR NEWSWIRE
07 Apr 2025

https://www.prnewswire.com/news-releases/neurelis-presents-studies-on-seizure-clusters-at-the-american-epilepsy-society-annual-meeting-302324997.html

PR NEWSWIRE
06 Dec 2024

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty